Interestingly, combining EBRT with anti-PD-L1 treatment, both concurrent and sequential dosing, did not cause significant increase in tumor growth control compared to the relevant irradiation only group; however, combination therapies did result in improved survival by minimising the onset and/or signs of tumor ulcerations. This evidence concerns the gene CD274 and neoplasm.